---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-323706"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-12-18T23:59:59+00:00"
generated_at: "2026-05-16T12:46:01.022653+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kalaris Therapeutics raises $50M in oversubscribed private placement; cash runway into Q3 2027

## Summary
- Raised ~$50M gross via 4.2M shares at $10.00/share and 800K pre-funded warrants at $9.9999.
- Pricing was at a premium to prior 5-day closing price on Nasdaq.
- Investors include ADAR1 Capital, Coastlands, Invus, RTW, Samsara BioCapital, Woodline Partners.
- Proceeds to advance TH103 for neovascular AMD and for working capital; cash runway to Q3 2027.
- Private placement expected to close Dec 19, 2025; registration rights to file after April 1, 2026.

## SEC filing metadata
- accession: 0001193125-25-323706
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-12-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/d48530d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-323706
- JSON: https://secwatch.observer/filing/0001193125-25-323706.json
- Plain text: https://secwatch.observer/filing/0001193125-25-323706.txt

## Key facts
- Equity Issuances
  Kalaris Therapeutics, Inc. issued pre-funded warrants to purchase 800,000 shares of warrant to certain Investors for $9.9999 per Pre-Funded Warrant.
  - Security: warrant
  - Shares: pre-funded warrants to purchase 800,000 shares
  - Purchaser: certain Investors
  - Consideration: $9.9999 per Pre-Funded Warrant
  source text: pre-funded warrants to purchase 800,000 shares of the Company’s common stock (the “Pre-Funded Warrants”) at a price of $9.9999 per Pre-Funded Warrant
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm
- Equity Issuances
  Kalaris Therapeutics, Inc. issued 4,200,000 shares of common stock to certain institutional accredited investors for $10.00 per Share.
  - Security: common stock
  - Shares: 4,200,000 shares
  - Purchaser: certain institutional accredited investors
  - Consideration: $10.00 per Share
  source text: the Company agreed to issue and sell to the Investors in a private placement an aggregate of 4,200,000 shares of the Company’s common stock, par value $0.0001 per share (the “Shares”), at a price of $10.00 per Share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1754068/000119312525323706/0001193125-25-323706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.